Trial Profile

A Phase II Study Comparing Efficacy And Safety Of 5-Day Guadecitabine (SGI-110) Regimen Versus 10-day Guadecitabine (SGI-110) Regimen In Treatment-Naive Acute Myeloid Leukemia (TN-AML) Patients Who Were Not Candidates For Intensive Chemotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
12 Dec 2017 Results assessing the Predictors of Response and Survival in AML patients Treated with Guadecitabine (n=206) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
04 Feb 2017 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com